Form 4: Health Catalyst General Counsel Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Benjamin Landry, General Counsel of Health Catalyst, Inc., sold 2,387 shares of common stock at a price of $6.7105 per share on June 6, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On June 6, 2024, Benjamin Landry, the General Counsel of Health Catalyst, Inc. (HCAT), sold 2,387 shares of the company's common stock.
- The sale was executed at a price of $6.7105 per share.
- This transaction was conducted under a pre-arranged written trading plan adopted on March 1, 2024, in accordance with Rule 10b5-1.
- Following the transaction, Landry still beneficially owns 104,625 shares of Health Catalyst common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by executives are a normal part of corporate governance. The use of a 10b5-1 plan suggests the executive is selling at predetermined times and prices to avoid insider trading concerns.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2024-03-01 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2024-06-06 | Date of the stock sale transaction. |
| 2024-06-12 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.